Cargando…

Treatment of chronic hepatitis B naïve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial)

CONTEXT: Current drugs for chronic hepatitis B therapy have a poor efficacy in terms of post-treatment sustained viral suppression and generate important side effects during and after therapy. Therapeutic vaccination with HBV antigens is an attractive alternative to test. OBJECTIVE: Evaluating the e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al Mahtab, Mamun, Akbar, Sheikh Mohammad Fazle, Aguilar, Julio Cesar, Guillen, Gerardo, Penton, Euduaro, Tuero, Angela, Yoshida, Osamu, Hiasa, Yoichi, Onji, Morikazu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104936/ https://www.ncbi.nlm.nih.gov/pubmed/30133478 http://dx.doi.org/10.1371/journal.pone.0201236

Ejemplares similares

Sustained Antiviral and Liver Protection by a Nasal Therapeutic Vaccine (NASVAC, Containing Both HBsAg and HBcAg) in Patients with Chronic Hepatitis B: 2-Year Follow-Up of Phase III Clinical Trial
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2021)

Intranasal HBsAg/HBcAg-Containing Vaccine Induces Neutralizing Anti-HBs Production in Hepatitis B Vaccine Non-Responders
por: Shiraishi, Kana, et al.
Publicado: (2023)

Antiviral Response across Genotypes after Treatment of Chronic Hepatitis B Patients with the Therapeutic Vaccine NASVAC or Pegylated Interferon
por: Al-Mahtab, Mamun, et al.
Publicado: (2023)

The Safety and Efficacy of a Therapeutic Vaccine for Chronic Hepatitis B: A Follow-Up Study of Phase III Clinical Trial
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2021)

Development of Therapy Based on the Exploration of Biological Events Underlying the Pathogenetic Mechanisms of Chronic Hepatitis B Infection
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2023)

Safety profile, antiviral capacity, and liver protection of a nasal therapeutic vaccine in patients with chronic hepatitis B: Five-year-follow-up outcomes after the end of treatment
por: Al Mahtab, Mamun, et al.
Publicado: (2023)

Innovative Therapies Targeting the Virus and the Host for Treating Chronic Hepatitis B Virus Infection: From Bench to Bedside
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2022)

Role of Pegylated Interferon in Patients with Chronic Liver Diseases in the Context of SARS-CoV-2 Infection
por: Akbar, Sheikh MF, et al.
Publicado: (2021)

Characterization of Liver Monocytic Myeloid-Derived Suppressor Cells and Their Role in a Murine Model of Non-Alcoholic Fatty Liver Disease
por: Yao, Liying, et al.
Publicado: (2016)

Development of Therapeutic Vaccine for Chronic Hepatitis B: Concept, Cellular and Molecular Events, Design, Limitation, and Future Projection
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2022)

T Helper 17 Cells in Autoimmune Liver Diseases
por: Abe, Masanori, et al.
Publicado: (2013)

Immune therapies against chronic hepatitis B
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2022)

Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients
por: Cerva, Carlotta, et al.
Publicado: (2022)

HBsAb and HBcAb Have No Significant Effect on the Progression of SLE and RA
por: WANG, Fen, et al.
Publicado: (2017)

Implications of Birth-Dose Vaccination against Hepatitis B Virus in Southeast Asia
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2021)

EDITORIAL
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2019)

Evaluation of HBs-Ag and anti-HBc levels in serum and saliva of patients with hepatitis B
por: Gharavi, Matine, et al.
Publicado: (2020)

The Journal in the Horizon of Asia and Europe
por: Fazle Akbar, Sheikh Mohammad, et al.
Publicado: (2018)

Cellular and Molecular Mechanisms of Pathogenic and Protective Immune Responses to SARS-CoV-2 and Implications of COVID-19 Vaccines
por: Akbar, Sheikh Mohammad Fazle, et al.
Publicado: (2023)

Prevalence of HBc-Ab among HBs-Ag negative healthy blood donors in south of Iran
por: Khorami, Farhad, et al.
Publicado: (2013)

De novo hepatitis B surface antigen (HBsAg)-positive, core antibody (anti-HBc)-negative, hepatitis B virus infection post-liver transplant from an anti-HBc, HBsAg-negative donor
por: Bedi, Harjot K., et al.
Publicado: (2021)

Hepatitis B Reactivation in a HBsAg-Negative, HBcAb-Positive Patient Receiving Fludarabine for the Treatment of Chronic Lymphocytic Leukaemia
por: Toscanini, Federica, et al.
Publicado: (2011)

B cell activating factor in obesity is regulated by oxidative stress in adipocytes
por: Tada, Fujimasa, et al.
Publicado: (2013)

The Properties of Red Blood Cells from Patients Heterozygous for HbS and HbC (HbSC Genotype)
por: Hannemann, A., et al.
Publicado: (2011)

Treatment of Nonalcoholic Steatohepatitis by Obeticholic Acid: Current Status
por: Roy, Partho Pratik, et al.
Publicado: (2022)

Prevalence of Anti-HBc Antibodies among HBsAg Negative Individuals and Its Association with Occult Hepatitis B
por: Madhavan, Anitha, et al.
Publicado: (2021)

Increased B Cell-Activating Factor Promotes Tumor Invasion and Metastasis in Human Pancreatic Cancer
por: Koizumi, Mitsuhito, et al.
Publicado: (2013)

Protein Kinase R Modulates c-Fos and c-Jun Signaling to Promote Proliferation of Hepatocellular Carcinoma with Hepatitis C Virus Infection
por: Watanabe, Takao, et al.
Publicado: (2013)

Action Mechanisms and Scientific Rationale of Using Nasal Vaccine (HeberNasvac) for the Treatment of Chronic Hepatitis B
por: Aguilar, Julio Cesar, et al.
Publicado: (2022)

Moderate Risk of Hepatitis B Virus Reactivation in HBsAg(−)/HBcAb(+) Carriers Receiving Rituximab for Rheumatoid Arthritis
por: Kuo, Meng Hsuan, et al.
Publicado: (2020)

Epidemiology of Hepatitis E Virus in an Urban Community in Dhaka City
por: Rahman, Salimur, et al.
Publicado: (2014)

Cation Homeostasis in Red Cells From Patients With Sickle Cell Disease Heterologous for HbS and HbC (HbSC Genotype)
por: Hannemann, A., et al.
Publicado: (2015)

Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis
por: Morisco, Filomena, et al.
Publicado: (2014)

RE: Risk of HBV Reactivation in HBsAg Negative and Anti-HBc IgG Positive Patients Receiving Biologic Therapy
por: Ergenç, İlkay, et al.
Publicado: (2023)

Therapy Targeting Stem Cell in Patients with Decompensated Cirrhosis of Liver in a Tertiary Treatment Care Center of Bangladesh
por: Al Mahtab, Mamun, et al.
Publicado: (2017)

Quantitative anti-HBc combined with quantitative HBsAg can predict HBsAg clearance in sequential combination therapy with PEG-IFN-α in NA-suppressed chronic hepatitis B patients
por: Wang, Wen-Xin, et al.
Publicado: (2022)

Role of tenofovir and telbivudine in treatment of hepatitis B related acute on chronic liver failure
por: Malakar, Debraj, et al.
Publicado: (2021)

Unprecedented rise of monkeypox in Europe and America: Are Asian countries ready for a new outbreak during the ongoing COVID-19 pandemic?
por: Khan, Sakirul, et al.
Publicado: (2022)

Association between anti-HBc positivity and hepatocellular carcinoma in HBsAg-negative subjects with chronic liver disease: A meta-analysis
por: Coppola, Nicola, et al.
Publicado: (2016)

Hepatitis B virus reactivation in HBsAg-negative, anti-HBc-positive patients receiving immunosuppressive therapy: a systematic review
por: Cholongitas, Evangelos, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vfelusipugmekqm2vk9rjqruq6